In their study, 41 patients with metastatic cancer were injected with granulocyte-macrophage colony-stimulating factor (GM-CSF, a type of immune-based therapy) and received fractionated IR on one of the tumor lesions. The gene discussed is CSF2; the disease is neoplasm.